Nexthera Capital LP bought a new position in shares of Ovid Therapeutc (NASDAQ:OVID) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 30,543 shares of the company’s stock, valued at approximately $320,000. Nexthera Capital LP owned approximately 0.12% of Ovid Therapeutc as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in OVID. Bank of New York Mellon Corp acquired a new stake in shares of Ovid Therapeutc during the 2nd quarter worth $135,000. TIAA CREF Investment Management LLC acquired a new stake in shares of Ovid Therapeutc during the 2nd quarter worth $142,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Ovid Therapeutc during the 2nd quarter worth $153,000. OxFORD Asset Management LLP acquired a new stake in shares of Ovid Therapeutc during the 2nd quarter worth $189,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Ovid Therapeutc during the 2nd quarter worth $204,000. 32.44% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research lowered Ovid Therapeutc from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $23.50.

Ovid Therapeutc (OVID) traded up 0.35% during mid-day trading on Thursday, reaching $8.64. The company had a trading volume of 12,624 shares. The stock’s market capitalization is $212.56 million. The stock has a 50 day moving average price of $8.28 and a 200-day moving average price of $10.12. Ovid Therapeutc has a 12-month low of $5.28 and a 12-month high of $15.93.

Ovid Therapeutc (NASDAQ:OVID) last posted its earnings results on Thursday, August 10th. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.09). Equities analysts anticipate that Ovid Therapeutc will post ($3.88) EPS for the current fiscal year.

In other Ovid Therapeutc news, CEO Jeremy M. Levin bought 15,334 shares of Ovid Therapeutc stock in a transaction that occurred on Friday, August 25th. The stock was acquired at an average cost of $7.15 per share, for a total transaction of $109,638.10. Following the completion of the transaction, the chief executive officer now directly owns 4,601,529 shares in the company, valued at $32,900,932.35. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/05/30543-shares-in-ovid-therapeutc-ovid-acquired-by-nexthera-capital-lp.html.

Ovid Therapeutc Company Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Want to see what other hedge funds are holding OVID? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ovid Therapeutc (NASDAQ:OVID).

Institutional Ownership by Quarter for Ovid Therapeutc (NASDAQ:OVID)

Receive News & Stock Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related stocks with our FREE daily email newsletter.